233 related articles for article (PubMed ID: 29998615)
1. Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma.
Patatsos K; Shekhar TM; Hawkins CJ
Vet Comp Oncol; 2018 Dec; 16(4):544-553. PubMed ID: 29998615
[TBL] [Abstract][Full Text] [Related]
2. The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma in vitro.
Marley K; Helfand SC; Edris WA; Mata JE; Gitelman AI; Medlock J; Séguin B
BMC Vet Res; 2013 Jan; 9():15. PubMed ID: 23331343
[TBL] [Abstract][Full Text] [Related]
3. [Proteasome inhibitors in cancer therapy].
Romaniuk W; Ołdziej AE; Zińczuk J; Kłoczko J
Postepy Hig Med Dosw (Online); 2015 Dec; 69():1443-50. PubMed ID: 27259216
[TBL] [Abstract][Full Text] [Related]
4. Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs.
Hasinoff BB; Patel D
Cardiovasc Toxicol; 2018 Dec; 18(6):557-568. PubMed ID: 29951728
[TBL] [Abstract][Full Text] [Related]
5. Enrofloxacin enhances the effects of chemotherapy in canine osteosarcoma cells with mutant and wild-type p53.
York D; Withers SS; Watson KD; Seo KW; Rebhun RB
Vet Comp Oncol; 2017 Sep; 15(3):1087-1100. PubMed ID: 27333821
[TBL] [Abstract][Full Text] [Related]
6. Effect of proteasome inhibitors on canine lymphoma cell response to CHOP chemotherapy in vitro.
Prevedel NE; Mee MW; Wood GA; Coomber BL
Vet Comp Oncol; 2024 Mar; 22(1):96-105. PubMed ID: 38237918
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial.
Skorupski KA; Uhl JM; Szivek A; Allstadt Frazier SD; Rebhun RB; Rodriguez CO
Vet Comp Oncol; 2016 Mar; 14(1):81-7. PubMed ID: 24118677
[TBL] [Abstract][Full Text] [Related]
8. The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib.
Engür S; Dikmen M
Acta Clin Belg; 2017 Dec; 72(6):391-398. PubMed ID: 28327055
[TBL] [Abstract][Full Text] [Related]
9. Effects of the potassium-sparing diuretic amiloride on chemotherapy response in canine osteosarcoma cells.
Poon AC; Inkol JM; Luu AK; Mutsaers AJ
J Vet Intern Med; 2019 Mar; 33(2):800-811. PubMed ID: 30556178
[TBL] [Abstract][Full Text] [Related]
10. Clinical and marketed proteasome inhibitors for cancer treatment.
Zhang J; Wu P; Hu Y
Curr Med Chem; 2013; 20(20):2537-51. PubMed ID: 23531219
[TBL] [Abstract][Full Text] [Related]
11. [Role of novel proteasome inhibitors in the treatment of relapsed/refractory multiple myeloma].
Ri M
Rinsho Ketsueki; 2018; 59(10):2162-2168. PubMed ID: 30305522
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitors: structure and function.
Nunes AT; Annunziata CM
Semin Oncol; 2017 Dec; 44(6):377-380. PubMed ID: 29935898
[TBL] [Abstract][Full Text] [Related]
13. Next-generation proteasome inhibitors for cancer therapy.
Park JE; Miller Z; Jun Y; Lee W; Kim KB
Transl Res; 2018 Aug; 198():1-16. PubMed ID: 29654740
[TBL] [Abstract][Full Text] [Related]
14. Second Generation Proteasome Inhibitors in Multiple Myeloma.
Gozzetti A; Papini G; Candi V; Brambilla CZ; Sirianni S; Bocchia M
Anticancer Agents Med Chem; 2017; 17(7):920-926. PubMed ID: 27592543
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitors.
Teicher BA; Tomaszewski JE
Biochem Pharmacol; 2015 Jul; 96(1):1-9. PubMed ID: 25935605
[TBL] [Abstract][Full Text] [Related]
16. [Molecular targeting agents for multiple myeloma].
Fujii S; Abe M
Nihon Rinsho; 2012 Nov; 70 Suppl 8():518-23. PubMed ID: 23513894
[No Abstract] [Full Text] [Related]
17. Evaluation of toxicities from combined metronomic and maximal-tolerated dose chemotherapy in dogs with osteosarcoma.
Bracha S; Walshaw R; Danton T; Holland S; Ruaux C; Obradovich J
J Small Anim Pract; 2014 Jul; 55(7):369-74. PubMed ID: 24803081
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of copper chaperones sensitizes human and canine osteosarcoma cells to carboplatin chemotherapy.
Inkol JM; Poon AC; Mutsaers AJ
Vet Comp Oncol; 2020 Dec; 18(4):559-569. PubMed ID: 32060984
[TBL] [Abstract][Full Text] [Related]
19. Toxicity and efficacy of cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma.
Chun R; Garrett LD; Henry C; Wall M; Smith A; Azene NM
J Am Anim Hosp Assoc; 2005; 41(6):382-7. PubMed ID: 16267062
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib and Doxorubicin Show Synergistic Effects in Human and Canine Osteosarcoma Cell Lines.
Yang YT; Yuzbasiyan-Gurkan V
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]